Physician profile
Samir Desai
NPI 1417942301
$12,239.44
in general payments reported to CMS, 2019-2025
70 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $697 · 2021: $929 · 2022: $1,501 · 2023: $1,574 · 2024: $3,550 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,869 · Long Term Medical Supply Or Device Loan: $1,912 · Consulting Fee: $1,340 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,868.76 |
| Long Term Medical Supply Or Device Loan | $1,912.15 |
| Consulting Fee | $1,340.00 |
| Education | $262.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,674.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,610.50 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $568.23 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $523.98 | 2019-2024 | Lumakras, Kyprolis, Blincyto |
| Genentech USA, INC. | $488.98 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Merck Sharp & Dohme LLC | $431.73 | 2019-2025 | Keytruda, Lynparza |
| Incyte Corporation | $408.01 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $379.03 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Pfizer INC. | $351.45 | 2019-2025 | |
| Seagen INC. | $323.91 | 2019-2025 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $318.51 | 2019-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $270.61 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $234.99 | 2019-2024 | Alunbrig |
| Genzyme Corporation | $230.94 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $211.29 | 2019-2025 | Pyrukynd |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.